{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T21:22:22Z","timestamp":1794172942043,"version":"4.8.0"},"reference-count":9,"publisher":"Our Dermatology Online","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>ABSTRACT\n\nTirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, is used to treat type 2 diabetes mellitus. While gastrointestinal adverse effects are well established, cutaneous manifestations are less characterized. We report a case of a biopsy-confirmed exanthematous drug eruption associated with tirzepatide. A 74-year-old woman developed profuse watery diarrhea and an intensely pruritic rash shortly after initiating tirzepatide. Over three weeks, the eruption involved the bilateral upper extremities and proximal lower extremities. Histopathologic evaluation revealed superficial dermal perivascular dermatitis with eosinophils and mild epidermal spongiosis. Discontinuation of tirzepatide and topical corticosteroids led to clinical improvement. This case expands the limited literature on systemic dermatologic adverse effects of tirzepatide by demonstrating a biopsy-confirmed exanthematous drug eruption. Recognition of such reactions allows for prompt diagnosis and enhanced patient counseling. This represents one of the first reported biopsy-confirmed exanthematous drug eruptions associated with tirzepatide.\n\nKey words: Tirzepatide, GLP-1 receptor agonist, Cutaneous adverse drug reaction, Obesity pharmacotherapy, Dermatologic toxicity<\/jats:p>","DOI":"10.7241\/ourd.20264.17","type":"journal-article","created":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T21:10:27Z","timestamp":1794172227000},"source":"Crossref","is-referenced-by-count":0,"title":["Biopsy-confirmed diffuse exanthematous drug eruption following tirzepatide initiation: A case report"],"prefix":"10.7241","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0665-6663","authenticated-orcid":false,"given":"Kanika","family":"Garg","sequence":"first","affiliation":[{"name":"Philadelphia College of Osteopathic Medicine, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2210-4743","authenticated-orcid":false,"given":"Joyce","family":"J.Zhu","sequence":"additional","affiliation":[{"name":"USF Health Morsani College of Medicine, University of South Florida, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0731-5496","authenticated-orcid":false,"given":"Ritu","family":"Sidgal","sequence":"additional","affiliation":[{"name":"Lehigh Valley Hospital\u2013Cedar Crest, Lehigh Valley Health Network, Allentown, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"M.Nazif","sequence":"additional","affiliation":[{"name":"Lehigh Valley Hospital\u2013Cedar Crest, Lehigh Valley Health Network, Allentown, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4255","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.  Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse Effects of GLP-1 Receptor Agonists. Rev Diabet Stud. 2014;11:202-30.","DOI":"10.1900\/RDS.2014.11.202"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.  Mishra R, Raj R, Elshimy G, Zapata I, Kannan L, Majety P, et al. Adverse Events Related to Tirzepatide. J Endocr Soc. 2023;7:bvad016.","DOI":"10.1210\/jendso\/bvad016"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.  Mizumoto J. Tirzepatide-Induced Injection Site Reaction. Cureus. 2023;15:e45181.","DOI":"10.7759\/cureus.45181"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.  Le TTB, Minh LHN, Devi P, Islam N, Sachmechi I. A Case Report of Systemic Allergic Reaction to the Dual Glucose-Dependent Insulinotropic Polypeptide\/Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide. Cureus. 2024;16:e51460.","DOI":"10.7759\/cureus.51460"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.  Houssini GS, Douhi Z, Soughi M, Elloudi S, Baybay H, Moukafih B, et al. Severe cutaneous adverse drug reactions:A search for the culprit in a retrospective study of 107 patients. Our Dermatol Online. 2025;16:43.","DOI":"10.7241\/ourd.20251.6"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.  Adithyan P, Raghavendra BN, Kumar PA. Case series of a varied spectrum of drug reactions. Our Dermatol Online. 2023;14:416-9.","DOI":"10.7241\/ourd.20234.16"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.  P\u00e9rez Caldera OL, R\u00edos Restrepo JD, Reyes Sarmiento MS, Garc\u00eda Agudelo L. Toxicoderma \u2013 Case report and narrative literature review. Our Dermatol Online. 2025;16(Suppl. 2):34-40.","DOI":"10.7241\/ourd.2025S2.1"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.  Ernst M, Giubellino A. Histopathologic Features of Maculopapular Drug Eruption. Dermatopathology (Basel). 2022;9:111-21.","DOI":"10.3390\/dermatopathology9020014"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.  Stern RS. Exanthematous (morbilliform) drug eruption. N Engl J Med. 2012;366:2492\u2013501.","DOI":"10.1056\/NEJMcp1104080"}],"container-title":["Our Dermatology Online"],"original-title":[],"deposited":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T21:10:35Z","timestamp":1794172235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.odermatol.com\/issue-in-html\/2026-4-17-exanthematous_eruption\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":9,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.7241\/ourd.20264.17","relation":{},"ISSN":["2956-7904"],"issn-type":[{"value":"2956-7904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}